Novartis Gsk Deal
- All
- News
-
GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
Novartis Okays OTC Unit Sale to GSK Consumer
The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.
-
Novartis India Gains 5% as CCI Clears Deal with GSK
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business while the latter would purchase GSK's cancer drugs portfolio.
-
Novartis-GSK Pharma Deal Cleared by CCI
The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.
-
GSK says Novartis deal not to impact India business
The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.
-
Novartis reshapes business via deals with GSK and Lilly
The overhaul is part of a major realignment in the global pharmaceuticals industry as it strives to cope with a clampdown in health spending by cash-strapped governments.
-
Novartis India soars 20% on parent's deal with GSK, Eli Lilly
Novartis will acquire GSK's oncology products for a $14.5 billion. In a separate transaction, it will divest its animal health division to Eli Lilly for approximately $5.4 billion.
-
GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
Novartis Okays OTC Unit Sale to GSK Consumer
The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.
-
Novartis India Gains 5% as CCI Clears Deal with GSK
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business while the latter would purchase GSK's cancer drugs portfolio.
-
Novartis-GSK Pharma Deal Cleared by CCI
The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.
-
GSK says Novartis deal not to impact India business
The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.
-
Novartis reshapes business via deals with GSK and Lilly
The overhaul is part of a major realignment in the global pharmaceuticals industry as it strives to cope with a clampdown in health spending by cash-strapped governments.
-
Novartis India soars 20% on parent's deal with GSK, Eli Lilly
Novartis will acquire GSK's oncology products for a $14.5 billion. In a separate transaction, it will divest its animal health division to Eli Lilly for approximately $5.4 billion.
